ClinicalTrials.gg
RecruitingNCT07312630Updated Dec 31, 2025

Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies

An Early Phase 1 interventional study of LV009 Injection Infusion in Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia (ALL), Adult, sponsored by PersonGen BioTherapeutics (Suzhou) Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Early Phase 1, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 196 studies in Lymphoma, Non-Hodgkin with a site in China — 83 open to participants now, 110 under way, 14 of them phase 3. Lymphoma, Non-Hodgkin · China.

Planned enrollment
142nd of 183
19 · median 58
Started
2025
with 11 others
Phase 1
79 of 196
33 open now
Primary completion
2026-09
later than 50 of 109 live
Registered
181st of 196
by date

Among the 196 studies in Lymphoma, Non-Hodgkin with a site in China, this one is the 142nd largest by planned enrollment of the 183 interventional ones that give a count, is one of 12 that started in 2025, is one of 79 in phase 1, reaches primary completion later than 50 of the 109 other live ones, and was the 181st registered.

Lymphoma, Non-Hodgkin

2,289 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

83 of the 196 studies in Lymphoma, Non-Hodgkin with a site in China are open now. Recruiting first, the newest first:

77 more — sign in →

All 83 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 241 Lymphoma, Non-Hodgkin studies recruiting now, 141 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 196 studies in Lymphoma, Non-Hodgkin with a site in China, or all of them as a file.
02

Study summary

Evaluate the safety, pharmacokinetic (PK) characteristics, and pharmacodynamic (PD) characteristics of LV009 injection in subjects with relapsed/refractory CD19-positive hematologic malignancies.

Read the detailed description

Within each dose group, the next subject may be dosed after the previous subject has completed at least 14 days of safety observation. Following the assessment of dose-limiting toxicity (DLT) within 28 days after the last subject in each dose group completed a single dose, and upon approval by the Safety Review Committee (SRC) based on clinical safety data to proceed to the next dose group, enrollment and treatment for the next dose group may commence. If one DLT occurs among the first three subjects in a dose group, three additional subjects must be added to that group (bringing the total to six subjects for DLT assessment): If no DLT occurs in the 3 additional subjects, dose escalation continues. If 1 DLT occurs in the 3 additional subjects, dose escalation is halted. If >1 DLT occurs in the 3 additional subjects, dose escalation is halted, and the dose must be reduced by one level to continue enrolling 3 subjects for DLT assessment.

03

Conditions studied

  • Non-Hodgkin Lymphoma (NHL)
  • Acute Lymphoblastic Leukemia (ALL), Adult

Keywords

  • CD19
  • CAR-T
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 70 years old (inclusive of both age limits), no gender restrictions, no racial restrictions
  • Expected survival time exceeds 12 weeks
  • performance status 0-2
  • Meets the NCCN guidelines' criteria for recurrence/ disease and is diagnosed with CD19-positive hematologic , including non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL)
  • Liver and kidney function, as well as cardiopulmonary function, meet requirements.
  • Absolute lymphocyte count ≥ 0.5 × 10⁹/L; count ≥ 50 × 10⁹/L; CD3-positive T cells ≥ 150 cells/μL.
  • Subjects must have a body temperature ≤ 38°C (excluding tumor fever) within 24 hours prior to study drug infusion and must not have significant active infection.
  • Within 5 days prior to the study drug infusion, subjects must not receive therapeutic doses of (>5 mg/day of prednisone or other equivalent doses of corticosteroids) or other agents.

Exclusion criteria

Exclusion Criteria:

  • Patients deemed by the investigator to require long-term use of agents during screening should be excluded.
  • Patients who have experienced a cerebrovascular accident or seizure within the six months prior to signing the form must be excluded.
  • Patients with malignant tumors other than the study disease must be excluded (only patients with carcinoma in situ may be considered for inclusion).
  • surface antigen (HBsAg) positive; Hepatitis B core antibody (HBcAb) positive with peripheral blood hepatitis B virus (HBV) DNA titer outside normal reference range; virus (HCV) antibody positive with peripheral blood hepatitis C virus (HCV) RNA positive; (HIV) antibody positive; Cytomegalovirus (CMV) DNA positive; Syphilis positive. (Patients meeting any criterion in this section must be excluded.)
  • Patients with severe cardiac conditions must be excluded, including but not limited to: unstable angina, myocardial infarction (within 6 months prior to screening), congestive heart failure ( [NYHA] class ≥ III), and severe arrhythmias.
  • Patients judged by the investigator to have unstable systemic diseases must be excluded, including but not limited to those with severe liver, kidney, or metabolic diseases requiring medication.
  • Patients with chronic progressive neurological diseases should be excluded.
  • Patients who have not recovered from acute toxic effects following prior treatment must be excluded.
  • Patients with active infections requiring systemic treatment or uncontrolled infections should be excluded (patients with mild urogenital tract infections and upper respiratory tract infections may be considered for inclusion).
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (estimated)

Study arms

  • Experimental
    Injection of CD19-Targeted Chimeric Antigen Receptor T Cells

    A dose escalation was conducted using four fixed doses of LV009 injection solution: 0.3 × 10\^9, 0.6 × 10\^9, 1.2 × 10\^9, and 2.4 × 10\^9 TU.

    Biological: LV009 Injection Infusion

Interventions

  • BiologicalLV009Studies of LV009LV009 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A dose escalation was conducted using four fixed doses of LV009 injection solution: 0.3 × 10\^9, 0.6 × 10\^9, 1.2 × 10\^9, and 2.4 × 10\^9 TU.

06

What researchers measure

Primary outcomes

  1. TEAE

    According to the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0

    Time frame: From the start of infusion of the study drug to 3 months after drug infusion

Secondary outcomes

  1. (Tmax)

    Time to peak concentration of CD19 CAR-T expansion in peripheral blood following administration of LV009 injection

    Time frame: Within 28 days after the transfusion and within 90 days after the transfusion

  2. (Cmax)

    Maximum concentration of CD19 CAR-T expansion in peripheral blood following administration of LV009 injection

    Time frame: Within 28 days after the transfusion and within 90 days after the transfusion

  3. AUC

    Area under the curve of CD19 CAR-T expansion in peripheral blood 28 days after administration of LV009 injection

    Time frame: Within 28 days after administration of LV009 injection

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Because the patent rights have not yet been determined.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Sep 2026, 12 months after the start.

Of 163 industry-sponsored phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 71. This study's planned 12 months is below that.

Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2025
First posted
Dec 31, 2025
StartActual
Sep 25, 2025
Primary completionEst.
Sep 25, 2026
CompletionEst.
Dec 12, 2027
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07312630
Responsible party
Sponsor
First posted
Dec 31, 2025
Start date
Sep 25, 2025
Primary completion
Sep 25, 2026 (estimated)
Completion
Dec 12, 2027 (estimated)
Last update
Dec 31, 2025

Study contacts

Xingbing Wang, Doctor
Contact
wangxingbing@ustc.edu.cn
+86-13856007984

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LV009

Start the discussion